MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
July 22, 2021 16:05 ET | MacroGenics, Inc.
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
February 25, 2021 16:01 ET | MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics-Logo-(transparent-background).png
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
December 18, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 16, 2020 16:30 ET | MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
November 04, 2020 16:01 ET | MacroGenics, Inc.
ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
July 30, 2020 16:01 ET | MacroGenics, Inc.
ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
July 23, 2020 07:30 ET | MacroGenics, Inc.
Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
July 09, 2020 18:43 ET | MacroGenics, Inc.
Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
June 22, 2020 09:00 ET | MacroGenics, Inc.
Rockville, MD, June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
June 05, 2020 07:30 ET | MacroGenics, Inc.
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...